OR WAIT null SECS
The technology is designed to enable patients to self-inject biologic-based therapies at home instead of a hospital setting.
On Feb. 7 2023, Elektrofi, a biotechnology company focused on drug formulation and delivery innovations, announced a contract manufacturing agreement with Thermo Fisher Scientific to support the manufacturing of Elektrofi’s ultra-high concentration subcutaneous products.
The technology is designed to enable patients to self-inject biologic-based therapies at home instead of a hospital setting. The new collaboration will facilitate the establishment of a platform current good manufacturing practice (CGMP) line and is scheduled to be operational in early 2024. This is intended to support early clinical efforts across a variety of pipeline programs and enable rapid scale-up for late-stage and commercial development.
“We are eager to begin investigating our subcutaneous delivery technology in human clinical trials to explore how it can positively impact the healthcare space, both by easing the burden on patients and caregivers and by improving therapeutic outcomes,” said Chase Coffman, CEO and co-founder of Elektrofi, in a press release. “To successfully initiate clinical development, we need to establish certified CGMP manufacturing capabilities. We’re thrilled to partner with Thermo Fisher, a global leader in development and manufacturing, to meet this goal and continue advancing our efforts to change the way biologic-based drugs are delivered.”
Elektrofi’s proprietary microparticle technology enables small-volume injections for biologics, like monoclonal antibodies or other large-molecule drugs. The technology is intended to help overcome the need for patients to get treated at hospitals or infusion centers.
“Our expertise in drug development and manufacturing will help Elektrofi pioneer a significant advance in how medicine is introduced into patients,” said Leon Wyszkowski, president of Commercial Operations, Pharma Services for Thermo Fisher Scientific, in a press release. “We deeply appreciate their confidence in us and look forward to the clinical research progress we will make together."